Physio 4.5
Cardiovascular Disease (CVD): Overview
Public Health Impact: CVD is the leading cause of death for both men and women in the United States and represents a significant public health burden.
Economic Cost: The annual cost associated with CVD exceeds , accounting for healthcare services, medications, and lost productivity.
Pathological Context: It is a major contributor to and consequence of various physiological disruptions, including hyperlipidemia, atherosclerosis, and hypertension.
Hyperlipidemia and Lipoproteins
Definitions and Classification:
Hyperlipidemia: An excess of lipids in the blood. Lipids include triglycerides, phospholipids, and cholesterol.
Hypercholesterolemia: Specifically refers to elevated levels of blood cholesterol. For medical purposes in this context, the terms hypercholesterolemia and hyperlipidemia are often used interchangeably.
Lipoprotein Structure and Function:
As cholesterol and triglycerides are insoluble in plasma, they require a stabilizing coat made of water-soluble phospholipids and proteins.
Apoproteins: The protein component that stabilizes the lipid particle.
Lipoproteins: The combined particle consisting of lipids and apoproteins. They transport lipids to tissues for energy utilization, lipid deposition, steroid hormone production, and bile acid formation.
Density Relationship: Lipoproteins are named by density. Proteins are denser than fats; therefore, as the protein content (density) increases, the triglyceride density decreases.
Types of Lipoproteins:
Chylomicrons: The largest particles; primarily carry triglycerides, with small amounts of phospholipids, cholesterol, and apoprotein B.
Very-Low-Density Lipoprotein (VLDL): Primarily carries triglycerides.
Intermediate-Density Lipoprotein (IDL): A transitional lipoprotein.
Low-Density Lipoprotein (LDL): Known as "bad cholesterol." It is the primary carrier of cholesterol. Approximately of LDL is removed from circulation by LDL receptors; the remainder is handled by monocytes/macrophages (scavenger cells).
High-Density Lipoprotein (HDL): Known as "good cholesterol." It carries cholesterol away from peripheral tissues back to the liver for excretion. There is an inverse relationship between HDL levels and atherosclerosis risk.
Lipoprotein Synthesis: Occurs primarily in the small intestine and the liver.
Clinical Presentation and Diagnostics of Hyperlipidemia
Factors Raising Blood Lipids: Elevated levels result from a multifactorial mix of nutrition, genetics, medications, comorbid conditions, and metabolic diseases.
Primary vs. Secondary Hypercholesterolemia:
Primary: Develops independently of other health problems, often due to genetic defects (synthesis of apoproteins, lack of/defective receptors, or intracellular cholesterol handling).
Secondary: Associated with other health problems or behaviors such as obesity, high-calorie intake, diabetes mellitus, hypothyroidism, nephrotic syndrome, and obstructive liver disease.
Familial Hypercholesterolemia (Type 2A):
An autosomal dominant disorder caused by deficient or defective LDL receptors.
Heterozygote levels: .
Homozygote levels: can exceed .
Xanthomas: Characteristic cholesterol deposits appearing in the skin, cornea, and tendons.
Drug-Induced Lipid Elevation: Medications such as beta-blockers, estrogens, and protease inhibitors (for HIV) can raise lipid levels.
NCEP Fasting Lipoprotein Profile Recommendations:
The National Cholesterol Education Program (NCEP) recommends all adults aged and older have a profile measured once every .
Classification of Blood Lipid Levels (Table 4.3):
LDL Cholesterol:
Optimal:
Near/Above Optimal:
Borderline High:
High:
Very High:
Total Cholesterol:
Desirable:
Borderline High:
High:
HDL Cholesterol:
Low:
High:
Triglycerides:
Normal:
Borderline High:
High:
Hyperlipidemia Management
Primary Target: Reduction in LDL cholesterol, particularly for those at risk for coronary heart disease (CHD).
Risk Factors for CHD: Smoking, hypertension, family history of premature CHD (first-degree relative), age (men ; women ), and HDL .
Lifestyle Changes: Usually trialed for before drug therapy (except in high-risk patients like those with diabetes).
Physical Activity: Increase regular exercise.
Weight Reduction and Smoking Cessation.
Dietary Restrictions: Decrease excess calories; saturated fat of total daily intake; trans fats of daily intake; cholesterol ; lower consumption of sugars, salt, and alcohol.
Dietary Emphasis: Fruits, vegetables, and fish.
Pharmacologic Treatment:
HMG CoA Reductase Inhibitors (Statins): (e.g., atorvastatin, rosuvastatin, simvastatin). Block hepatic synthesis of cholesterol. First-line for LDL reduction; also decrease triglycerides and increase HDL.
Bile Acid-binding Resins: (e.g., cholestyramine, colestipol, colesevelam). Sequester bile acids in the intestine, forcing the liver to use more blood cholesterol to synthesize new bile acids. Used as an adjunct to statins (increases HDL ).
Niacin (Vitamin B3): Blocks VLDL synthesis. Lowers VLDL, IDL, and LDL while increasing HDL (). Side effects include flushing and headache.
Fibrates: (e.g., fenofibrate, gemfibrozil). Decrease VLDL synthesis and increase triglyceride clearance from circulation (reduces triglycerides by ).
Cholesterol Absorption Inhibitor Agents: Direct intervention on dietary cholesterol intake.
Atherosclerosis: Pathology and Progression
Etymology: From Greek atheros ("gruel/paste") and sclerosis ("hardness").
Definition: A hardening of the arteries characterized by fibrofatty lesions in the lining of medium and large arteries (aorta, coronary arteries, large vessels supplying the brain).
Lesion Types:
Fatty Streaks: Thin, flat, yellow lines composed of macrophages and smooth muscle cells distended with lipids (foam cells). Present in childhood; can regress or develop into plaques.
Fibrous Atheromatous Plaques: The basic lesion of clinical atherosclerosis. Gray/pearly white appearance due to ingested oxidized lipoproteins. Consists of smooth muscle cells, macrophages, leukocytes, extracellular matrix (collagen, elastic fibers), and lipids. Occludes the vessel lumen.
Complicated Lesions: Occur when plaques break open, leading to hemorrhage, ulceration, and scar tissue. These trigger thrombosis.
Risk Factors:
Nonmodifiable: Increasing age, male gender, genetic disorders of lipid metabolism, family history of premature CAD.
Modifiable: Hyperlipidemia (elevated LDL, low HDL), cigarette smoking (causes endothelial damage), hypertension, obesity, diabetes mellitus.
Risk Multiplication: HTN or diabetes doubles risk; having both increases risk eight-fold.
Nontraditional/Inflammatory Markers:
C-reactive protein (CRP): General indicator of inflammation; elevated levels are associated with vascular disease.
Lipoprotein(a): Similar to LDL; promotes foam cell formation and cholesterol deposition in plaques.
Vessel Vulnerability: "Unstable plaques" have a large central lipid core, inflammatory infiltrate, and a thin fibrous cap, making them prone to rupture.
Clinical Complications: Typically appear after development begins. Complications include ischemia, infarction, aneurysm (weakening of the vessel wall), and thrombus/emboli formation.
Hypertension: Guidelines and Classifications
The "Silent Killer": Patients are often asymptomatic until target-organ damage occurs (heart, eyes, kidneys, blood vessels).
JNC 8 Guidelines (Table 4.5):
Normal:
Elevated:
Hypertension Stage 1: systolic OR diastolic.
Hypertension Stage 2: systolic OR diastolic.
Hypertensive Crisis:
Urgency: systolic and/or diastolic.
Emergency: with evidence of target organ damage. Requires ICU and IV treatment.
Risk Factors:
Non-modifiable: Family history ( contribution), age, race (higher incidence in African Americans).
Modifiable: Obesity, high salt intake (American average is ; recommended is ), excessive alcohol, and low potassium intake.
Other conditions: Insulin resistance, obstructive sleep apnea, and secondary causes (renal artery stenosis, aldosteronism).
Clinical Manifestations and Management of Hypertension
Impact on the Heart: Increased workload leads to Left Ventricular Hypertrophy, a major risk factor for death.
Organ Damage:
Kidneys: Nephrosclerosis and hypoperfusion of the glomerulus.
Brain: Narrowing/sclerosis of small arteries, increasing risk of ischemic stroke, hemorrhage, dementia, and cognitive impairment.
Eyes: Hypertensive retinopathy, microvascular changes, papilledema, and arteriovenous (AV) nicking.
Diagnosis Protocols:
Measured on at least two separate occasions.
Patient must be rested for , with an empty bladder, and no smoking/caffeine/exercise for prior.
White Coat Hypertension: Elevated readings in-office due to nervousness; requires monitoring in different settings.
Lifestyle Modifications (Table 4.6):
Weight Reduction: BMI ; reduces BP by per lost.
DASH Eating Plan: High in fruits, vegetables, low-fat dairy; low in saturated/total fat ( reduction).
Sodium Reduction: Limit to sodium or sodium chloride ( reduction).
Physical Activity: aerobic activity most days ( reduction).
Alcohol Moderation: Limit to (men) or (women) per day ( reduction).
Pharmacologic Agents:
Thiazide Diuretics: Decrease vascular volume and cardiac output by inhibiting sodium reabsorption.
ACE Inhibitors: Block conversion of Angiotensin I to Angiotensin II; reduces vasoconstriction and aldosterone.
ARBs (Angiotensin II Receptor Blockers): Prevent Angiotensin II from binding to receptors.
CCBs (Calcium Channel Blockers): Inhibit calcium movement into cardiac/vascular smooth muscle; cause vasodilation and decreased heart rate/contractility.
Beta-blockers: Now considered second-line therapy.